# Program 34: Lung Cancer

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $40,758

## Abstract

Lung Cancer Program
Project Summary / Abstract
The Lung Cancer Program conducts innovative research on lung cancer causes and pathogenesis, focusing
on discoveries that improve prevention, diagnosis, and therapy. The Program leverages expertise across all
DF/HCC institutions in smoking cessation, lung cancer screening, genetic susceptibility, genomic changes in
lung cancer, preclinical and clinical studies of novel therapies, and molecular analysis of tumors before and
after targeted and immunotherapeutic agents. A core strength of the Program is an integral bidirectional link
between the laboratory and clinic, which has enabled insights into drug resistance and accelerated clinical
development of agents to overcome newly identified vulnerabilities. Community engagement is embedded in
the Program’s laboratory, preventive, cancer screening, and clinical efforts.
The Program’s 69 members (51 primary and 18 secondary) represent six DF/HCC institutions and 11
academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $6.5 million in
direct costs from the NCI and $2.6 million from other sponsors. During the current funding period, primary
Program members published 1,004 cancer-relevant papers. Of these, 27% were inter-institutional, 27% were
intra-programmatic, and 42% were inter-programmatic collaborations between two or more DF/HCC members.
To achieve the Program mission, we propose the following Specific Aims during the next CCSG funding
period: 1) Identify environmental, social, and genomic determinants of lung cancer risk and their role in
susceptibility, pathogenesis, and prognosis of lung cancer, both in underserved and broader populations; 2)
Define pathogenic mechanisms that underlie the development and evolution of lung cancer; 3) Exploit the
discoveries in cell biology to characterize signaling pathway activated by driver oncogenes to develop novel
therapeutic approaches to thoracic malignancies; 4) Characterize the mechanisms of primary and acquired
resistance to targeted therapy and develop new methods to overcome resistance; and 5) Identify critical
tumor-intrinsic, tumor microenvironment, and host determinants of response to immunotherapy across lung
cancer subtypes.
Each of these Aims is intimately related to the DF/HCC strategic plan. To achieve them, Program members
will depend heavily on CCSG support in the form of shared resources, a clinical trials infrastructure,
exceptional collaborative opportunities, processes for community engagement, and established structures
to train junior investigators.

## Key facts

- **NIH application ID:** 10768690
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** BRUCE E. JOHNSON
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $40,758
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768690

## Citation

> US National Institutes of Health, RePORTER application 10768690, Program 34: Lung Cancer (5P30CA006516-59). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10768690. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*